TCTR20230621009已完成1 期
Pharmacokinetic of Apixaban Tablet 5 mg: An open label, randomized, crossover study on healthy subjects in fasting condition
Duopharma Biotech Berhad0 个研究点目标入组 26 人开始时间: 2023年6月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
The 90% confidence interval of Cmax, AUC0-t and AUC0-inf were within bioequivalence acceptance limit of 80-125%. Apixaban Tablet 5 mg is bioequivalent to reference product
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Able to participate, communicate well with the investigators, and would provide written informed consent to participate in the study
- •2. Healthy male and female subjects with the absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening and could be considered healthy based on the evaluation
- •3. Aged 18-55 years inclusive
- •4. Non smokers
- •5. Body mass index within 18.5 to 30 kg/m3
- •6. Normal prothrombin time (PT) and normal partial thromboplastin time (aPTT)
- •7. Creatinine clearance > 50 mL/min
- •8. Vital sign (after 10 minute rest) we were within the following ranges
- •i. Systolic blood pressure: 100-129 mmHg
- •ii. Diastolic blood pressure: 60-84 mmHg
- •iii. Pulse rate: 60-90 bpm
排除标准
- •1. History of allergy or hypersensitivity or contraindication to apixaban or factor Xa inhibitors or allied drugs.
- •2. Pregnant or lactating female (urinary pregnancy test was applied to female subjects at screening and before taking the study drug).
- •3. Any major illness in the past 90 days or clinically significant ongoing chronic medical illness
- •4. Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver function test, renal function test etc
- •5. Positive Hepatitis B surface antigen (HBsAg), anti-HCV, or anti-HIV.
- •6. Positive result for COVID-19 swab antigen test.
- •7. Clinically significant hematology abnormalities.
- •8. Clinically significant electrocardiogram (ECG) abnormalities
- •9. Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal disease including gastric or duodenal ulcers or history of gastric surgery.
- •10. Past history of anaphylaxis or angioedema
- •11. History of drug or alcohol abuse within 12 months prior to screening for this study.
- •12. Participation in any clinical trial within the past 90 days calculated from the last visit until this study's first dosing day
- •13. History of any bleeding or coagulative disorders.
- •14. History of significant head injury within the last two years
- •15. Presence of difficulty in accessibility of veins in left or right arm.
- •16. A donation or significant blood loss within 90 Presence of difficulty in accessibility of veins in left or right arm.
- •16. A donation or significant blood loss within 90 days before this study first dosing day.
- •17. Intake of any prescription (especially apixaban, other anticoagulants, azole antimycotics), non-prescription drug (including hormonal contraception), food supplements or herbal medicines within 21 days of this study first dosing day.
研究者
相似试验
已完成
1 期
Bioequivalence Study of a Generic Sitagliptin Phosphate Tablet 100 mgHealthy subjectsbioequivalence studySitagliptinTCTR20220621004Duopharma Biotech Berhad27
已完成
不适用
Bioequivalence of ApixabaIRCT20210201050197N4Shahid Beheshti University of Medical Sciences24
招募中
Unknown
Investigating the in vivo bioequivalence of Apixaban tabletIn the present study, the products will be administered to healthy volunteers..IRCT20220211053992N10Tabriz University of Medical Sciences24
已完成
不适用
Comparative in vivo evaluation of 2 ?Apixaban 5 mg Tablet formulations.IRCT20180620040164N37Actover Pharmaceutical Co.24
已完成
1 期
Bioequivalence Study of Generic Sitagliptin HCL Tablet 100 mgHealthy subjectsbioequivalence studygenericSitagliptin HCLSitagliptin HCTCTR20220628001Duopharma Biotech Berhad25